Managing Classical Hodgkin Lymphoma With Antibody-Drug Conjugates
Release Date: Thursday, February 28, 2019
Expire Date: Friday, February 28, 2020
Shared Decision-Making: How to Discuss Therapeutic Options With Your Patients Considering Treatment for Classical Hodgkin Lymphoma
Amy Goodrich, RN, MSN, CRNP-AC, and Kevin Nguyen, a patient who was treated for classical Hodgkin lymphoma, discuss his treatment journey from diagnosis through relapse and how shared decision-making between him and his health-care team played an important role in the process.
Estimated Time to Complete: 30 minutes
Role of Antibody-Drug Conjugates for Front-Line Therapy in Classical Hodgkin Lymphoma
Amy Goodrich, RN, MSN, CRNP-AC, and Nadia Khan, MD, discuss the role of antibody-drug conjugates in the treatment of classical Hodgkin lymphoma, including mechanism of action, recent approvals, emerging data, and expert guidance on clinical application.
Estimated Time to Complete: 30 minutes
Anticipating and Managing Side Effects for Patients With Classical Hodgkin Lymphoma
Amy Goodrich, RN, MSN, CRNP-AC, and Barbara Rogers, CRNP, MN, AOCN®, ANP-BC, review best practices for anticipating and managing side effects for patients being treated for classical Hodgkin lymphoma, including the short- and long-term adverse events associated with chemotherapy, checkpoint inhibitors, and antibody–drug conjugates.
Estimated Time to Complete: 30 minutes
